3 Stocks Raising The Health Services Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 83 points (-0.5%) at 16,448 as of Tuesday, May 6, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,223 issues advancing vs. 1,760 declining with 164 unchanged.

The Health Services industry currently sits down 0.1% versus the S&P 500, which is down 0.4%. Top gainers within the industry include WellCare Health Plans ( WCG), up 5.4%, CareFusion ( CFN), up 1.7%, Hologic ( HOLX), up 1.6% and Varian Medical Systems ( VAR), up 0.9%. A company within the industry that fell today was Fresenius Medical Care AG & Co. KGaA ( FMS), up 2.8%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Stryker Corporation ( SYK) is one of the companies pushing the Health Services industry higher today. As of noon trading, Stryker Corporation is up $0.52 (0.7%) to $79.35 on light volume. Thus far, 599,125 shares of Stryker Corporation exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $78.46-$79.43 after having opened the day at $78.60 as compared to the previous trading day's close of $78.83.

Stryker Corporation, together with its subsidiaries, operates as a medical technology company. The company operates in three segments: Reconstructive, MedSurg, and Neurotechnology and Spine. Stryker Corporation has a market cap of $29.5 billion and is part of the health care sector. The company has a P/E ratio of 38.5, above the S&P 500 P/E ratio of 17.7. Shares are up 4.9% year-to-date as of the close of trading on Monday. Currently there are 13 analysts who rate Stryker Corporation a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Stryker Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

These Stocks Are Ready to Reverse Course

Don't Get Out of Joint

Zimmer Biomet: Cramer's Top Takeaways

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Analyst Says Rival Bidder Could Emerge for Novadaq After Stryker Deal